Home > Improving access to, and completion of, hepatitis C treatment.

Public Health England. (2015) Improving access to, and completion of, hepatitis C treatment. London: Public Health England. 6 p. Turning evidence into practice series

PDF (Improving access to, and completion of, hepatitis C treatment)

New treatments for hepatitis C virus (HCV) infection have shorter, easier, oral regimens with fewer side effects and better outcomes. These represent a real opportunity to reduce the incidence of HCV-related cirrhosis and liver cancer among people already infected with HCV and to remove the virus from the ‘infection pool’, resulting in reduced transmission among people who inject drugs and the general population. Treating hepatitis C infection is an effective and cost-effective way to substantially reduce prevalence, especially in areas where it is high. Compliance with the new treatments is easier and can be further improved by well-planned support for patients.

Needle and syringe programmes (NSP) and opioid substitution treatment (OST) have been effective in capping English hepatitis C virus (HCV) rates at an average of around 50% among people who inject drugs.* There are wide geographical variations, with prevalence much higher in some cities and metropolitan areas. Sustained long-term increases in the coverage of NSP and OST could further reduce the virus’s prevalence.

The rate of treatment for hepatitis C in people who inject drugs is extremely low (just 3% of people estimated to be infected with chronic infections access treatment each year) but it can be improved by attention to assessment and engagement pathways, peer and other support, improved staff awareness and attitudes, and better access. Evidence also shows that addressing people’s healthcare needs, such as hepatitis, can help them progress in their drug recovery.

This briefing provides an overview of the key issues that local providers and commissioners of drug and hepatitis treatment should consider.

Item Type:Evidence resource
Publication Type:Guideline
Drug Type:Opioid
Intervention Type:AOD disorder harm reduction
Source:Public Health England
Date:July 2015
Pages:6 p.
Publisher:Public Health England
Corporate Creators:Public Health England
Place of Publication:London
Subjects:G Health and disease > Disorder by cause > Communicable disease > Hepatitis C
J Health care, prevention and rehabilitation > Health related prevention > Health information and education > Communicable disease control
J Health care, prevention and rehabilitation > Patient care management
J Health care, prevention and rehabilitation > Treatment and maintenance > Treatment factors
J Health care, prevention and rehabilitation > Health care delivery
MP-MR Policy, planning, economics, work and social services > Policy > Policy on substance use > Harm reduction policy
N Communication, information and education > Information transfer > Information transfer from research to practice
T Demographic characteristics > Intravenous / injecting drug user
VA Geographic area > Europe > United Kingdom > England

Repository Staff Only: item control page